Research programme: anticancer antibodies - EvoGenix/Viventia Biotech

Drug Profile

Research programme: anticancer antibodies - EvoGenix/Viventia Biotech

Alternative Names: Anticancer antibodies research programme - EvoGenix/Viventia Biotech

Latest Information Update: 03 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EvoGenix; Viventia Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Nov 2007 Discontinued - Preclinical for Cancer in Australia (unspecified route)
  • 03 Nov 2007 Discontinued - Preclinical for Cancer in Canada (unspecified route)
  • 14 Jun 2004 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top